格隆汇1月28日丨华宝国际(00336.HK)公告，华宝香精股份公布截至2025年12月31日止年度之业绩预 告。归属于华宝股份股东的净利润：6500~9500万元。报告期内，华宝股份实现归属于上市公司股东的 净利润扭亏为盈。2024年度，华宝股份业绩亏损主要由于食用香精-烟草用香精相关资产组计提商誉减 值损失。2025年度，华宝股份整体经营情况保持稳定，主营业务有序开展，内部管理持续优化，经管理 层初步评估，于2025年12月31日，华宝股份商誉不存在进一步重大减值风险。 ...

Group 1 - The core viewpoint of the article indicates that China Boton (03318) may consider a goodwill impairment loss of no less than approximately RMB 750 million for its tobacco flavoring business for the fiscal year ending December 31, 2025 [1] - The decline in revenue for the tobacco flavoring business is attributed to both self-developed tobacco flavoring products and a deteriorating overall market environment [1] - The company has adopted a prudent forecast for future sales of the tobacco flavoring business based on applicable accounting principles, leading to the estimated goodwill impairment loss [1]

Core Viewpoint - The company, China Boton (03318), announced a potential impairment loss of approximately RMB 750 million for its tobacco flavoring business as of December 31, 2025, due to reduced revenue from self-developed tobacco flavoring and a deteriorating overall market environment [1] Financial Impact - The estimated impairment loss may lead to a loss attributable to equity holders of the company for the year ending December 31, 2025 [1] Business Performance - The decline in revenue for the tobacco flavoring business is attributed to both the company's own product development and adverse market conditions [1]

Group 1 - The company, China Boton (03318.HK), announced a potential impairment loss of approximately RMB 750 million for its tobacco flavoring business due to a decline in revenue caused by self-developed tobacco flavoring and a deteriorating overall market environment [1] - The impairment loss is based on prudent forecasts of future sales for the tobacco flavoring business, in accordance with applicable accounting principles [1] - This impairment loss may result in a loss attributable to equity holders of the company for the fiscal year ending December 31, 2025 [1]

Group 1 - The core viewpoint of the news is that Huabao Holdings has shown a positive stock performance, with a 1.09% increase, reaching a price of 18.51 yuan per share, and a total market capitalization of 11.4 billion yuan [1] - Huabao Holdings, established on June 27, 1996, and listed on March 1, 2018, specializes in the research, production, and sales of flavorings, with its main business revenue composition being 54.53% from food flavorings, 32.45% from food additives, and 13.02% from daily flavorings [1] Group 2 - From the perspective of Huabao Holdings' top ten circulating shareholders, Huashang Fund's Huashang Quality Value Mixed A Fund (019189) has entered the top ten shareholders, holding 1.1624 million shares, which is 0.19% of the circulating shares [2] - The Huashang Quality Value Mixed A Fund has achieved a year-to-date return of 49.04%, ranking 1281 out of 8085 in its category, and a one-year return of 47.36%, ranking 1217 out of 8085 [2] - The fund manager, Yu Yi, has a tenure of 3 years and 111 days, with the fund's total asset size being 8.229 billion yuan, and the best return during his tenure being 81.1% [2]

Core Viewpoint - The company is advancing its health strategy through the establishment of dual bases in Jiangxi and Shandong, which will enhance its operational capabilities in the health sector [1] Group 1: Strategic Development - The dual bases will create a collaborative model of "front-end market traction + back-end R&D and manufacturing support" [1] - The northern base in Shandong will focus on market engagement and deep customer service, enabling quick responses and precise connections with key clients [1] - The southern base in Jiangxi will leverage a mature industrial chain to enhance product technology, upgrade production capacity, and strengthen the supply chain [1] Group 2: Product and Technology Focus - The company aims to provide a comprehensive solution from functional raw materials to diversified end products through the synergy of the two bases [1] - Research and development will focus on natural flavors, functional ingredients, traditional Chinese medicine extraction, and synthetic biology to accelerate technology transfer and industrialization [1] Group 3: Future Outlook - The company plans to continue enhancing its entire industry chain layout, integrating upstream raw materials, functional ingredients, and customized end products [1] - Strengthening ecological collaboration is expected to lay a more solid foundation for the ongoing expansion in the health sector [1]

Core Viewpoint - The company emphasizes the importance of strategic determination and business synergy for high-quality development in a complex global economic environment, with a focus on diversified layout and stable operations [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of approximately 1.621 billion yuan, representing a year-on-year increase of 2.5% [1] - The profit attributable to equity holders reached approximately 118 million yuan, showing a significant year-on-year growth of 298.1%, indicating strong operational resilience [1] Business Segments - The flavor and food ingredients segment, as a core area, has strengthened its technical capabilities in microwave drying and extraction, effectively meeting the demand for natural extracts from Chinese tea beverage brands [3] - In the tobacco raw materials segment, the new reconstituted tobacco leaf production line at the Indonesian production base has achieved bulk supply, with steadily increasing capacity utilization, serving as a key driver for sustainable development [3] - The tobacco capsule business is actively expanding into overseas markets, achieving rapid revenue growth through the development of region-specific flavors and technological upgrades [3] - The flavor raw materials segment has maintained stable revenue amidst fluctuations in overseas market demand through cost control and new customer development [3] - The seasoning business focuses on value innovation in the catering channel, enhancing customer engagement through online live broadcasts and offline promotional activities, with the number of primary distributors reaching 956 [3] Innovation and Risk Management - The company's philosophy of balancing technological innovation and risk management is reflected in its mid-term performance, with R&D investment of approximately 125 million yuan, accounting for 7.7% of revenue, and multiple technological achievements reaching industry-leading levels [4] - The company has optimized processes and improved systems across various dimensions, including climate change, safety production, and compliance, while integrating AI technology into operational management to enhance intelligence and digitalization, effectively reducing operational risks [4] - Cash generated from operating activities reached 214 million yuan, a year-on-year increase of 88.6%, with a maintained low debt-to-asset ratio, indicating a robust financial structure that provides ample funding for future development [4] Future Outlook - The company plans to continue deepening multi-business collaborative development under the strategic guidance of its CEO, focusing on the health sector and overseas market expansion, while enhancing core competitiveness through technological innovation and refined management to create greater value for shareholders [4]

Core Viewpoint - Huabao Co., Ltd. (300741) is focusing on its core business of research, production, and sales in the fields of flavors and food ingredients, while maintaining a prudent approach towards non-core business investments [1] Group 1 - The company emphasizes its commitment to core business areas and aims for steady operational development [1] - Huabao will adhere to a cautious principle regarding investments in non-core businesses, ensuring compliance with information disclosure standards when necessary [1]

Core Viewpoint - Huabao Co., Ltd. (300741) emphasizes that its daily chemical fragrances are widely used in personal care and cosmetics, and the specific effects and uses of end products containing its fragrance components should be based on official statements and promotions [1] Group 1 - The company produces daily chemical fragrances that are applicable in various fields, particularly personal care and cosmetics [1]

Group 1 - The company has technical reserves for improving the taste and flavor of its pharmaceutical products, which have already been applied to its offerings [1] - Specific customer cooperation details are not disclosed due to commercial confidentiality agreements, and stakeholders are advised to refer to the company's regular reports and announcements for major customer composition and business conditions [1]